Goldman Sachs, Morgan Stanley Bullish on BioAge, Cite Lilly Relationship
Novo Nordisk Semaglutide Cut Cardio Risks by 14% in Diabetics: Study
Report: novo-nordisk a/s weight loss drug Ozempic's 'sister drug' significantly reduces heart disease risk in experiments.
Patients with type 2 diabetes and a history of heart disease, chronic kidney disease, etc., have a 14% lower probability of experiencing cardiovascular events after taking Rybelsus compared to patients taking a placebo.
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk Says Its Rybelsus Oral Semaglutide Reduces Risk of Major Adverse Cardiovascular Events
Catalent's Maselli to Continue as CEO Post Novo Holdings Deal Close
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}